HC-58 ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 149 | Hemiconvulsion hemiplegia epilepsy syndrome | 1 |
149. Hemiconvulsion hemiplegia epilepsy syndrome
Clinical trials : 25 / Drugs : 40 - (DrugBank : 14) / Drug target genes : 17 - Drug target pathways : 20
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT01623622 (ClinicalTrials.gov) | July 2012 | 18/6/2012 | Study of HC-58 in Upper Limb Hemiplegic Patients After Stroke | A Phase 2 Study of HC-58 in Patients With Severe Upper Limb Hemiplegia After Stroke | Severe Upper Limb Hemiplegia | Drug: HC-58;Drug: Placebo | Asahi Kasei Pharma Corporation | NULL | Completed | 20 Years | N/A | All | 270 | Phase 2 | Japan |